title: Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy.
abstract: OBJECTIVE
  To study the influence of angiotensin (Ang) II receptor antagonist (AT1) valsartan and angiotensin-converting enzyme (ACE) inhibitor fosinopril on the cardiac hypertrophy induced by catecholamine.
  
  
  METHODS
  A cardiac hypertrophy model was produced by i.p. norepinephrine (NE) 1.5 mg.kg-1.d-1 x 15 d. The animals were divided into four groups: 1) control (sodium chloride), 2) NE, 3) NE + fosinopril, 4) NE + valsartan. Fosinopril ig 15 mg.kg-1.d-1 x 15 d, valsartan ig 30 mg.kg-1.d-1 x 15 d.
  
  
  RESULTS
  Valsartan ig 30 mg.kg-1.d-1 x 15 d and fosinopril ig 15 mg.kg-1.d-1 x 15 d prevented left ventricular hypertrophy induced by NE and decreased the content of collagen in myocardium; valsartan and fosinopril both elevated the myosin ATPase activity, Na+, K(+)-ATPase activity in membrane, and Ca(2+)-ATPase activity in mitochondrias. Apoptosis was induced in cardiomyocytes by catecholamine. Valsartan and fosinopril both inhibited apoptosis, and no significant differences were found in the apoptotic index between the two treatment groups.
  
  
  CONCLUSIONS
  Valsartan and fosinopril prevent the remodeling of cardiac hypertrophy induced by norepinephrine. Cardiac myocyte apoptosis may play a key role in the heart remodeling.
authors.affiliation: Department of Cardiology, Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Xiang
authors.forename: J
authors.initials: J
authors.lastname: Huang
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D000252:Calcium-Transporting ATPases / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D005260:Female; D017328:Fosinopril / Q000494:pharmacology*; D017379:Hypertrophy, Left Ventricular / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009638:Norepinephrine; D051381:Rats; D017207:Rats, Sprague-Dawley; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology*; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology*; D000068756:Valsartan; D020257:Ventricular Remodeling
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D013777:Tetrazoles; D000068756:Valsartan; D003094:Collagen; D000252:Calcium-Transporting ATPases; D000254:Sodium-Potassium-Exchanging ATPase; D014633:Valine; D017328:Fosinopril; D009638:Norepinephrine